

shall be considered by the Office if filed by the applicant after the period specified in paragraph (b) of this section, provided that the information disclosure statement is filed before the mailing date of either a final action under §1.113, or a notice of allowance under §1.311, whichever occurs first and is accompanied by either:

. . .

(2) The fee set forth in §1.17(p).

The Marchuk, D.A., Current Opinion in Hematology, 5: 332-338 (1998) article submitted herewith cites as reference 34 to Pece et al., J. Clin. Invest., 100(10): 2568-2579 (Nov. 1997). A copy of Pece et al., which is cited on PTO form 1449, also accompanies this Supplementary IDS.


Accompanying this statement is a request for payment by credit card of the fee as set forth in § 1.17(p). Should any additional fees be determined to be necessary in connection with this paper, Applicants respectfully request that any such additional fees be charged to Deposit Account No. 12-0615.

Applicants respectfully submit that the "filing of an information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in Section 1.56(b)" [37 CFR Section 1.97(h)]; and that an information disclosure statement filed in accordance with 37 CFR Section 1.97 "shall not be construed as a representation that a search has been made." [37 CFR Section 1.97(g)]


Further the identification of any document herein is not intended to be, and, Applicants respectfully submit, should not be construed as being, an admission that such a document, in fact, constitutes "prior art" within the meaning of the applicable laws, since, for example, a given document may have a later effective date than at first seems apparent, or the document may have an effective date which can be antedated. Applicants respectfully conclude on this point that the "prior art" status of any document is a matter to be resolved during prosecution.

Thus, Applicants respectfully conclude that the citation of references herein is not intended to be an admission that any of the references are considered to be material or to constitute prior art, or that any of the references either alone or in combination with any other references would be sufficient to render any of the claims of the above-identified patent application unpatentable.

Respectfully submitted,


Leona L. Lauder
Attorney for Applicants
Registration No. 30,863

Dated: March 9, 2004



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

CATX-N

Application Number

09/480,389

Applicant(s)

Bruce M. Boman

Filing Date

January 11, 2000

Group Art Unit

1642

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Marchuk, D.A., "Genetic abnormalities in hereditary hemorrhagic telangiectasia," Current Opinion in Hematology, 5: 332-338 (1998)

Pece et al., "Mutant Endoglin in Hereditary Hemorrhagic Telangiectasia Type 1 Is Transiently Expressed Intracellularly and Is Not a Deominant Negative," J. Clin. Invest., 100(10): 2568-2579 (Nov. 1997)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.